Neo.. Thanks for your analysis
Also since this trial is under Special Protocol Assessment by FDA, if they meet primary end point then FDA approval is guaranteed.. No ifs or buts
USA market is 110,000 so assuming pxs gets 10% of it.. That's 110M revenue and EBIT around 75M alone.
Their primary end point is 25% reduction in excarbations from 2 to 1.5 or less (25%). Hopefully this can't be too hard to achieve consider their CF patients resulted in excarbations per patient less than 1.
9year low..., page-35
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
